Katharina Richard, Barbara J Mann, Aiping Qin, Eileen M Barry, Robert K Ernst, Stefanie N Vogel
, a bacterial biothreat agent, has no approved vaccine in the United States. Previously, we showed that incorporating lysates from partially attenuated LVS or fully virulent Schu S4 strains into catanionic surfactant vesicle (V) nanoparticles (LVS-V and Schu S4-V, respectively) protected fully against LVS intraperitoneal (i.p.) challenge in mice. However, we achieved only partial protection against Schu S4 intranasal (i.n.) challenge, even when employing heterologous prime-boost immunization strategies. We now extend these findings to show that both LVS-V and Schu S4-V immunization (i.p./i.p.) elicited similarly high titers of anti- IgG and that the titers could be further increased by adding monophosphoryl lipid A (MPL), a nontoxic Toll-like receptor 4 (TLR4) adjuvant that is included in several U.S. FDA-approved vaccines. LVS-V+MPL immune sera also detected more antigens than LVS-V immune sera and, after passive transfer to naive mice, significantly delayed the time to death against Schu S4 subcutaneous (s.c.) but not i.n. challenge. Active immunization with LVS-V+MPL (i.p./i.p.) also increased the frequency of gamma interferon (IFN-��)-secreting activated helper T cells, IFN-�� production, and the ability of splenocytes to control intramacrophage LVS replication Active LVS-V+MPL immunization via heterologous routes (i.p./i.n.) significantly elevated IgA and IgG levels in bronchoalveolar lavage fluid and significantly enhanced protection against i.n. Schu S4 challenge (to ���60%). These data represent a significant step in the development of a subunit vaccine against the highly virulent type A strains.
